aluminum hydroxide
Trade name: Gaviscon
Small moleculeapproved
Approved
Dec 9, 1983
The ALOIN A (barbaloin) is considered to be the most specific secondary phytoconstituent in Aloe species, widely distributed throughout the world. Barbaloin has been found to have a strong inhibitory effect on histamine release from mast cells. Orally administered barbaloin is poorly absorbed but is metabolized by intestinal microflora to aloe emodin, which is readily absorbed. Barbaloin is the main medicinal constituent of aloe vera, which has anti-inflammatory activity. Moreover, it has strong anti-oxidant and anti-tumor properties. For example, barbaloin inhibited the proliferation and metastasis of non-small cell lung carcinoma cells in vivo and in vitro. Barbaloin demonstrated a cardioprotective potential: barbaloin pretreatment attenuates myocardial ischemia-reperfusion injury. Plus, it might be used as an antiarrhythmic drug. — NCATS
Clinical trial activity
138 trials · 156 clinical orgs · 6 marketing orgs
Phase 1
97
Phase 2
40
Phase 3
10
Phase 4
8
Earliest trial started Apr 1, 1999 (NCT00001906)
Timeline
1980s
- Dec 9, 1983
Earliest FDA Approval
- Dec 9, 1983
Sanofi-Aventis — NDA Secondary Org
- Dec 9, 1983
Sanofi — NDA Secondary Org
- Sep 4, 1987
Guardian Drug — Marketing Organization
- Jun 28, 1989
Novartis — Marketing Organization
1990s
- Jan 1, 1999
Earliest Phase 1 Sponsor(trial)
Indications
Approved for
Studied for
- Alzheimer Disease · Phase 1
- Anthrax · Phase 2
- Anus Neoplasms · Phase 3
- Brain Ischemia · Phase 3
- Caliciviridae Infections · Phase 1
- Campylobacter Infections · Phase 1
- Cerebrospinal Fluid Leak · Phase 3
- Chikungunya Fever · Phase 2
- Chikungunya virus · Phase 3
- Clostridium Infections · Phase 2
- Condylomata Acuminata · Phase 3
- Conjunctivitis · Phase 1
- Constipation · Phase 3
- COVID-19 · Phase 4
- Dengue · Phase 1
- Dermatitis, Atopic · Phase 4
- Diabetes Mellitus · Phase 4
- Diabetes Mellitus, Type 1 · Phase 2
- Diabetic Foot · Phase 4
- Diphtheria · Phase 2
- Diphtheria Toxoid · Phase 2
- Dyspepsia · Phase 4
- Dysuria · Phase 3
- Emergencies · Phase 4
- Enterovirus Infections · Phase 2
- Esophagitis · Phase 3
- Flavivirus Infections · Phase 1
- Gastroesophageal Reflux · Phase 4
- Head and Neck Neoplasms · Phase 1/Phase 2
- Healthy Volunteers · Phase 1/Phase 2
- Hemorrhoids · Phase 3
- Hepatitis B · Phase 1/Phase 2
- HIV · Phase 1
- HIV-1 · Phase 1
- HIV Infections · Phase 1/Phase 2
- Hookworm Infections · Phase 2
- Hypercholesterolemia · Phase 1
- Infections · Phase 1
- Influenza A Virus, H5N1 Subtype · Phase 1
- Influenza A Virus, H7N9 Subtype · Phase 2
- Influenza, Human · Phase 1/Phase 2
- Influenza Vaccines · Phase 1/Phase 2
- Leishmaniasis, Cutaneous · Phase 1
- Malaria · Phase 1/Phase 2
- Malaria, Falciparum · Phase 1/Phase 2
- Meningococcal Infections · Phase 1
- Multiple System Atrophy · Phase 1
- Neoplasms · Phase 3
- Neurodegenerative Diseases · Phase 1
- Norovirus · Phase 1
- Pain · Phase 4
- Papillomaviridae · Phase 1/Phase 2
- Parkinson Disease · Phase 1
- Plague · Phase 1
- Pneumococcal Infections · Phase 2
- Pneumonia, Pneumococcal · Phase 2
- Prostatic Neoplasms · Phase 1
- Pulmonary Disease, Chronic Obstructive · Phase 2
- Pulmonary Emphysema · Phase 2
- Respiratory Syncytial Virus Infections · Phase 1
- Respiratory Tract Diseases · Phase 2
- Respiratory Tract Infections · Phase 2
- Rheumatic Fever · Phase 1
- Rhinitis, Allergic · Phase 1
- RNA Virus Infections · Phase 2
- Schistosoma mansoni · Phase 1/Phase 2
- Schistosomiasis · Phase 1/Phase 2
- Severe Acute Respiratory Syndrome · Phase 1
- Stomatitis · Phase 4
- Streptococcal Infections · Phase 1
- Subarachnoid Hemorrhage · Phase 3
- Tetanus · Phase 2
- Tobacco Use Disorder · Phase 2
- Vasculitis · Phase 1
- Vasospasm, Intracranial · Phase 3
- Virus Diseases · Phase 2
- Whooping Cough · Phase 2
- Zika Virus · Phase 1
- Zika Virus Infection · Phase 1
Mechanism of action
- Unspecified targetOTHER
Antacid
- Unspecified targetOTHER
Unknown
Combination products
gaviscon
Also known as foamcoat, foamicon
Approval history
- approvedDec 9, 1983
Chemistry & pharmacology
Loading structure…
SMILES
O[Al](O)O- Mol. weight
- 78 g/mol
- Chirality
- Achiral Molecule
- Inorganic
- Yes
- Polymer
- No
- Delivery
- Oral
- Availability
- Discontinued
Oral
Yes
Parenteral
No
Topical
No
Sources
- WikipediaAluminium hydroxide ↗
- NCATSW41H6S09F4 ↗
- ChEMBLCHEMBL1200706 ↗
Also known as
- 10-(1,5'-anhydroglucosyl)aloe-emodin-9-anthrone
- adjuvanted pbs
- alginate - aluminium hydroxide - magnesium trisilicate - sodium bicarbonate
- alginate, aluminium hydroxide, magnesium trisilicate, sodium bicarbonate drug combination
- alginic acid, mixt. with aluminum hydroxide, silicic acid (h4si3o8) magnesium salt (1:2) and sodium hydrogen carbonate
- alhydrogel
- alhydrogel
- alloin
- al(oh)3
- aloin
- aloin
- aloin
- aloin
- aloin a
- aloin b
- aloinium
- alu-cap
- alu-cap
- alucol
- aludrox
- aludrox
- aludrox
- aluminium hydroxide
- aluminium hydroxide
- aluminium hydroxide
- aluminium hydroxide
- aluminium hydroxide, dried
- aluminium hydroxide, dried
- aluminium hydroxide gel, dried
- aluminium hydroxide gel, dried
- aluminum hydroxide
- aluminum hydroxide
- aluminum hydroxide
- aluminum hydroxide
- aluminum hydroxide
- aluminum hydroxide
- aluminum hydroxide
- aluminum hydroxide
- aluminum hydroxide
- aluminum hydroxide
- aluminum hydroxide, dried
- aluminum hydroxide gel, dried
- aluminum hydroxide gel, dried
- aluminum hydroxide hydrate
- aluminum hydroxide - magnesium hydroxide
- aluminum hydroxide, magnesium hydroxide, drug combination
- aluminum magnesium hydroxide
- amphojel
- amphojel
- dialume
- dialume
- dried aluminium hydroxide
- dried aluminium hydroxide
- dried aluminum hydroxide gel
- dried aluminum hydroxide gel
- gastrocote
- gaviscon
- gaviscon
- gaviscon
- imescard
- maalox
- maaloxan
- maaloxon
- maalox tc
- magnesium aluminum hydroxide
- magnesium aluminum hydroxide
- magnesium aluminum hydroxide
- neutralon
- novalucol
- quigel
- sarpep
- supralox
- xolaam
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07221162 | Phase 1 | Nov 17, 2025 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT06866574 | Phase 3 | Apr 11, 2025 | Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., Fudan University, Government of China, Xiamen University |
| NCT06680479 | Phase 1 | Feb 15, 2025 | Access to Advanced Health Institute (AAHI), Duke University, National Institute of Allergy and Infectious Diseases (NIAID), University of Pittsburgh |
| NCT06613789 | Phase 1 | Feb 3, 2025 | HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), University of Washington |
| NCT06267872 | Phase 1 | Oct 7, 2024 | Access to Advanced Health Institute (AAHI), Department of Health and Human Services, Duke University, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) |
| NCT06241183 | Phase 4 | Nov 9, 2023 | Stony Brook University |
| NCT05901636 | Phase 1/Phase 2 (Phase 2) | May 17, 2023 | Department of Health and Human Services, Janssen Pharmaceutica NV |
| NCT05776017 | Phase 1/Phase 2 (Phase 2) | Mar 27, 2023 | Malaria Research and Training Center, Bamako, Mali, Vac4All |
| NCT05876195 | N/A | Mar 1, 2023 | University of Oxford |
| NCT05561673 | Phase 1/Phase 2 (Phase 2) | Oct 4, 2022 | GlaxoSmithKline |
| NCT05228314 | Phase 1 | May 30, 2022 | Clover Biopharmaceuticals |
| NCT05197751 | Phase 1 | Dec 1, 2021 | Vac4All |
| NCT05108571 | Phase 1 | Nov 3, 2021 | Dong-A Pharmaceutical |
| NCT05098275 | Phase 1 | Oct 29, 2021 | Dong-A Pharmaceutical |
| NCT05098262 | Phase 1 | Oct 26, 2021 | Dong-A Pharmaceutical |
| NCT05098886 | Phase 1 | Oct 26, 2021 | Dong-A Pharmaceutical |
| NCT05065983 | Phase 2 | Oct 11, 2021 | Emergent BioSolutions |
| NCT05072080 | Phase 3 | Sep 29, 2021 | Emergent BioSolutions |
| NCT05012787 | Phase 3 | Sep 13, 2021 | Clover Biopharmaceuticals |
| NCT04985760 | Phase 1 | Aug 17, 2021 | National Institute of Allergy and Infectious Diseases (NIAID), University of Pittsburgh |
Showing 20 of 138 trials
Page 1 / 7
Organizations
Research & Development (156)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 44 | 35 | 3 | 1999 |
| Baylor University | Academic/Hospital | 9 | 9 | 2 | 2005 |
| George Washington University | Academic/Hospital | 7 | 0 | 2 | 2005 |
| GlaxoSmithKline | For profit | 6 | 4 | 2 | 1999 |
| Affiris AG | For profit | 5 | 5 | 1 | 2007 |
| Dong-A Pharmaceutical | For profit | 4 | 4 | 1 | 2021 |
| Government of China | Government | 4 | 0 | 3 | 2017 |
| China National Biotec Group Co., Ltd | For profit | 3 | 2 | 2 | 2017 |
| Clover Biopharmaceuticals | For profit | 3 | 3 | 2 | 2020 |
| Duke University | Academic/Hospital | 3 | 1 | 2 | 2010 |
| HIV Vaccine Trials Network | Academic/Hospital | 3 | 1 | 2 | 2017 |
| Institut National de la Santé Et de la Recherche Médicale, France | Academic/Hospital | 3 | 2 | 1 | 2014 |
| Johns Hopkins University | Academic/Hospital | 3 | 0 | 1 | 2006 |
| Medicago | For profit | 3 | 2 | 2 | 2012 |
| Merck | For profit | 3 | 2 | 1 | 2012 |
| National Institutes of Health (NIH) | Government | 3 | 0 | 2 | 2006 |
| PharmAthene | For profit | 3 | 3 | 2 | 2005 |
| United States Army | Government | 3 | 1 | 1 | 2003 |
| University of Oxford | Academic/Hospital | 3 | 3 | 3 | 2010 |
| University of Pittsburgh | Academic/Hospital | 3 | 2 | 1 | 2007 |
156 organizations
Page 1 / 8
Marketing (6)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Guardian Drug | For profit | MKTG | Sep 4, 1987 |
| Merrell Dow | For profit | NDA | — |
| Novartis | For profit | MKTG | Jun 28, 1989 |
| PENNEX | For profit | MKTG | — |
| Sanofi | For profit | NDA2 | Dec 9, 1983 |
| Sanofi-Aventis | For profit | NDA2 | Dec 9, 1983 |